Viatris Inc.
VTRS
Clasificación en acciones
#1098
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Precio por acción
$18.45
Capitalización bursátil
$21.19B
Cambio (1 día)
1.04%
Cambio (1 año)
78.95%
País
US
Comercio Viatris Inc. (VTRS)
Categoría
Healthcare
Ganancias de Viatris Inc. (VTRS)
Ganancias en Jun 2026 TTM: $-662.20M
Secondo gli ultimi rapporti finanziari di Viatris Inc., gli utili attuali della società sono $-662.20M. Nel 2023, la società ha registrato un utile di $202.90M, una disminución en comparación con agli utili del 2022, che erano di $2.81B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Viatris Inc. desde 2004 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-662.20M | 6.26% |
| 2024 | $-623.20M | -407.15% |
| 2023 | $202.90M | -92.79% |
| 2022 | $2.81B | -523.42% |
| 2021 | $-664.40M | -7.88% |
| 2020 | $-721.20M | -567.10% |
| 2019 | $154.40M | -48.26% |
| 2018 | $298.40M | -66.95% |
| 2017 | $903.00M | 641.99% |
| 2016 | $121.70M | -86.71% |
| 2015 | $915.40M | -6.06% |
| 2014 | $974.50M | 30.40% |
| 2013 | $747.30M | -7.06% |
| 2012 | $804.08M | 22.83% |
| 2011 | $654.64M | 83.92% |
| 2010 | $355.94M | 56.82% |
| 2009 | $226.98M | -417.19% |
| 2008 | $-71.56M | -95.04% |
| 2007 | $-1.44B | -624.90% |
| 2006 | $274.61M | -12.06% |
| 2005 | $312.25M | -39.09% |
| 2004 | $512.61M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -366.47% |
IN
|
